

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.09.25.~2023.10.01.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 81건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06027879	Anti-viral T-cell Therapy by Gamma Capture	Biological: Specific T- Lymphocytes	Paul Szabolcs University of Pittsburgh	Phase 1 Phase 2	
NCT06026657	Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer	Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Gemcitabine Procedure: Magnetic Resonance Imaging Biological: Naxitamab Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells	Margaret Gatti-Mays Ohio State University Comprehensive Cancer Center	Phase 1 Phase 2	
NCT05957367	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies	Drug: DCC-3116 Drug: Ripretinib Drug: Cetuximab Drug: Encorafenib	Deciphera Pharmaceuticals LLC Pfizer	Phase 1 Phase 2	
NCT05920798	A Study of FRaDCs for Ovarian Cancer	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Biological: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine Biological: Pembrolizumab Procedure: Pheresis	Mayo Clinic	Phase 1 Phase 2	
NCT05890729	A Study of XTMAb-16 in Patients With Pulmonary Sarcoidosis	Drug: XTMAb-16 or Placebo	Xentria, Inc.	Phase 1 Phase 2	
NCT05845749	Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI	Drug: Vosoritide Injection [Voxzogo]	University of California, San Francisco	Phase 1 Phase 2	
NCT05756166	Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer	Procedure: Biopsy Procedure: Biospecimen Collection Drug: Celecoxib Procedure: Computed Tomography Biological: Interferon Alpha-2 Procedure: Magnetic Resonance Imaging Biological: Pembrolizumab Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2	
NCT04129515	NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis	Device: NovoTTF-200A Drug: Pembrolizumab	Brown University NovoCure Ltd.	Phase 1 Phase 2	
NCT03811886	Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma	Drug: Natalizumab	Case Comprehensive Cancer Center	Phase 1 Phase 2	
NCT05932199	Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma	Drug: Durvalumab / tremelimumab Drug: Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab	Baylor College of Medicine Duke Cancer Institute	Phase 1 Phase 2	
NCT06062966	The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)	Drug: Anakinra	Virginia Commonwealth University	Phase 1	
NCT06052176	Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement	Drug: Albumin	Hunter Holmes Mcguire Veteran Affairs Medical Center Grifols Biologicals, LLC	Phase 2	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 미국 81건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06058663	Radioembolization With Tremelimumab and Durvalumab for Locally Advanced, Unresectable Intrahepatic Cholangiocarcinoma	Procedure: Angiography Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Durvalumab Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Biological: Tremelimumab Procedure: Yttrium-90 Microsphere Radioembolization	Mayo Clinic National Cancer Institute (NCI)	Phase 1	
NCT06050915	A Study of DISC-3405 in Healthy Volunteers	Drug: DISC-3405 Drug: Placebo	Disc Medicine, Inc	Phase 1	
NCT06049576	Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma	Procedure: Biospecimen Collection Procedure: Bone Scan Procedure: Computed Tomography Biological: Ipilimumab Procedure: Magnetic Resonance Imaging Drug: Myrciaria dubia Prebiotic Supplement Biological: Nivolumab	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	
NCT06048484	Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma	Radiation: Stereotactic body radiotherapy (SBRT) Drug: Zimberelimab Drug: Quemliclustat Drug: Etrumadenant Drug: Modified FOLFIRINOX	Gulam Manji Arcus Biosciences, Inc. Columbia University	Phase 2	
NCT06047886	CD34 Selection Using the Automated CliniMACS Prodigy	Drug: Infusion of CD34 selected hematopoietic stem cells	University of Alabama at Birmingham	Phase 1	
NCT06042725	Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Chest Radiography Procedure: Computed Tomography Biological: Daratumumab Drug: Dexamethasone Drug: Lenalidomide Procedure: Low Dose Computed Tomography of the Whole Body Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Drug: Venetoclax Procedure: X-Ray Imaging	Mayo Clinic	Phase 1	
NCT06038526	Evaluation of Canakinumab in High-Risk Former-Smokers	Procedure: Biospecimen Collection Procedure: Bronchoscopy Biological: Canakinumab Procedure: Carbon Monoxide Measurement Other: Survey Administration	Peter Shields Ohio State University Comprehensive Cancer Center	Phase 2	
NCT06027268	Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer	Drug: Trilaciclib Drug: Pembrolizumab Drug: Gemcitabine Drug: Carboplatin	Wake Forest University Health Sciences Merck Sharp & Dohme LLC G1 Therapeutics, Inc.	Phase 2	
NCT06027229	Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations	Biological: NVX-CoV2372	University of Wisconsin, Madison Novavax	Phase 2	
NCT06015724	Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer	Drug: Daratumumab Biological: KRAS vaccine Drug: Nivolumab	Georgetown University Bristol-Myers Squibb Janssen, LP Targovax ASA	Phase 2	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 미국 81건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06002503	Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection	Drug: Venezuelan Equine Encephalitis DNA Vaccine Device: PharmaJet Stratis Needle-free Injection System Device: PharmaJet Tropis Needle-free Injection System	PharmaJet, Inc.	Phase 1	
NCT06001853	Allogeneic BM-MSC's in Patients With Lumbar Facet Arthropathy	Drug: BM-MSC injection Drug: DSMO Injection	Mayo Clinic	Phase 2	
NCT05981209	Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Drug: Dexamethasone Procedure: Echocardiography Biological: Elotuzumab Procedure: Magnetic Resonance Imaging Biological: Mezigdomide Procedure: X-Ray Imaging	Abdullah Khan Ohio State University Comprehensive Cancer Center	Phase 1	
NCT05973734	Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy	Biological: Infusion of recipient T regulatory cell Biological: Infusion of concomitant Donor Derived Vertebral Bone Marrow	Stanford University University of California, San Francisco	Phase 1	
NCT05956041	Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas	Drug: Pembrolizumab Drug: Mogamulizumab	University of Michigan Rogel Cancer Center Merck Sharp & Dohme LLC Hoosier Cancer Research Network	Phase 2	
NCT05954143	Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer	Drug: BDC-1001 Drug: Pertuzumab	Bolt Biotherapeutics, Inc. Hoffmann-La Roche	Phase 2	
NCT05948826	First in Human Study of TORL-3-600 in Participants With Advanced Cancer	Drug: TORL-3-600	TORL Biotherapeutics, LLC Translational Research in Oncology	Phase 1	
NCT05928806	Advanced Renal Cell Cancer Combination ImmunoTherapy Clinical Trial	Drug: Botensilimab Drug: Balstilimab Drug: Ipilimumab Drug: Nivolumab	Michael B. Atkins, MD Agenus Inc. Georgetown University Hoosier Cancer Research Network	Phase 2	
NCT05922904	PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma	Drug: Brentuximab vedotin Drug: Doxorubicin Hydrochloride Drug: Pembrolizumab Drug: Dacarbazine	M.D. Anderson Cancer Center Merck Sharp & Dohme LLC Seagen Inc.	Phase 2	
NCT05903092	MONalIZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer	Drug: Durvalumab Drug: Monalizumab Drug: Carboplatin or Cisplatin Drug: Etoposide	Hirva Mamdani AstraZeneca Barbara Ann Karmanos Cancer Institute Hoosier Cancer Research Network	Phase 2	
NCT05901545	Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer	Biological: Panitumumab Other: Indium In 111 Panitumumab Procedure: Single Photon Emission Computed Tomography Procedure: Computed Tomography Procedure: Surgical Procedure Other: Imaging agent Procedure: Intraoperative Imaging Procedure: Near Infrared Imaging Procedure: Electrocardiography Procedure: Biospecimen Collection	Vanderbilt-Ingram Cancer Center American Cancer Society, Inc.	Phase 1	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 미국 81건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05887882	Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Brain Tumors	Biological: Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells Procedure: Implantation	Sabine Mueller, MD, PhD Rally Foundation Washington University School of Medicine Nationwide Children's Hospital University of California, San Francisco	Phase 1	
NCT05871970	Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age	Biological: TARA-002	Protara Therapeutics	Phase 2	
NCT05870761	Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma	Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Dostarlimab Procedure: Magnetic Resonance Imaging Drug: Niraparib	Casey Cosgrove Ohio State University Comprehensive Cancer Center	Phase 2	
NCT05854498	Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer	Drug: Liposomal irinotecan Drug: TAS102 Drug: Bevacizumab	University of Wisconsin, Madison psen	Phase 2	
NCT05834244	A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)	Drug: Azacitidine Drug: Venetoclax Drug: NK Cells	M.D. Anderson Cancer Center	Phase 1	
NCT05812924	A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause	Biological: Platelet-rich plasma (PRP)	University of Miami	Phase 2	
NCT05799612	Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma	Drug: Paclitaxel Biological: mRNA plus Lysate-loaded Dendritic Cell Vaccine Drug: PEGYLATED-INTERFERON ALPHA-2A Drug: Filgrastim	M.D. Anderson Cancer Center Cancer Cures 4 Kids	Phase 1	
NCT05799144	pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer	Biological: DNA Vaccine Biological: Human Papillomavirus Tumor Antigen Vaccine Biological: Pembrolizumab Procedure: Computed Tomography (CT) Procedure: Magnetic Resonance Imaging (MRI) Procedure: Magnetic Resonance Imaging Procedure: Biopsy	Michael K. Gibson Vanderbilt-Ingram Cancer Center	Phase 2	
NCT05776979	Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients	Drug: Isatuximab Drug: lenalidomide	M.D. Anderson Cancer Center Sanofi	Phase 2	
NCT05775471	Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer	Procedure: Biopsy Procedure: Biospecimen Collection Drug: Enfortumab Vedotin Procedure: MR Urography Procedure: Nephroureterectomy Biological: Pembrolizumab	Jonsson Comprehensive Cancer Center Merck Sharp & Dohme LLC Seagen Inc.	Phase 2	
NCT05770531	Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy	Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Biological: Sacituzumab Govitecan	Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI)	Phase 2	
NCT05766371	Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer	Drug: Pembrolizumab Drug: 177Lu-PSMA-617	University of California, San Francisco Merck Sharp & Dohme LLC Prostate Cancer Foundation	Phase 2	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 미국 81건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05757843	Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab	Diagnostic Test: Signatera ctDNA test Drug: Durvalumab	Indiana University	Phase 2	
NCT05681195	Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas	Drug: Pemetrexed Drug: Zanubrutinib Procedure: Autologous Stem Cell Transplant (ASCT) Radiation: Whole Brain Radiation Therapy (WBRT)	Baptist Health South Florida BeiGene	Phase 2	
NCT05669846	Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC	Drug: Fecal Microbiota Transplant (FMT) Drug: Pembrolizumab	Diwakar Davar Gateway for Cancer Research University of Pittsburgh	Phase 2	
NCT05629546	Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors	Biological: Memory-like natural killer cells Biological: Relatlimab Biological: Nivolumab	Washington University School of Medicine	Phase 1	
NCT05537402	LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC	Drug: Atezolizumab and bevacizumab Radiation: transarterial chemoembolization (TACE) or transarterial radioembolization (TARE)	University of Texas Southwestern Medical Center Genentech, Inc.	Phase 2	
NCT05534646	Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer	Drug: Apalutamide Drug: Carotuximab	Edwin Posadas, MD Enviro Therapeutics, Inc. Cedars-Sinai Medical Center	Phase 2	
NCT05491226	Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation	Drug: Pembrolizumab Radiation: Radiation Therapy Drug: Axatilimab	Stephen Shiao Merck Sharp & Dohme LLC Incyte Corporation Cedars-Sinai Medical Center	Phase 2	
NCT05457959	Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant	Biological: Dendritic Cell Tumor Peptide Vaccine Biological: Ipilimumab Procedure: Leukapheresis Biological: Nivolumab Drug: Placebo Administration Drug: Poly ICLC Procedure: Resection	Jonsson Comprehensive Cancer Center	Phase 1	
NCT04881240	Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia	Biological: CD19-CAR(Mem) T-cells Drug: Cyclophosphamide Drug: Fludarabine Drug: Mesna Device: CliniMACS Procedure: Leukapheresis	St. Jude Children's Research Hospital	Phase 1	
NCT04448106	Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis	Biological: Celltex- AdMSCs	Celltex Therapeutics Corporation	Phase 2	
NCT03463239	Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora	Biological: Autologous tissue engineered corpora	Wake Forest University Health Sciences United States Department of Defense	Phase 1	
NCT06043674	A Phase 2 Study of Glofitamab as Monotherapy or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation	Drug: Glofitamab Drug: Obinutuzumab Drug: Polatuzumab Vedotin Drug: Atezolizumab Drug: Tocilizumab	Matthew S. Davids, MD Genentech, Inc. Dana-Farber Cancer Institute	Phase 2	
NCT06006013	Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer	Biological: Atezolizumab Procedure: Biopsy Procedure: Biospecimen Collection Drug: Cabozantinib S-malate Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging	Emory University National Cancer Institute (NCI)	Phase 2	
NCT05706116	Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults	Biological: Trichuris trichiura Egg Inoculum	George Washington University National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 미국 81건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06052852	Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies	Drug: BDC-3042 Drug: Pembrolizumab	Bolt Biotherapeutics, Inc.	Phase 1 Phase 2	
NCT05814666	Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC	Drug: Danvatirsen Drug: Pembrolizumab	Flamingo Therapeutics NV	Phase 2	
NCT05715229	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy	Drug: Nivolumab Drug: Ipilimumab Drug: Carboplatin Drug: Paclitaxel Drug: Pemetrexed	Hackensack Meridian Health MedSIR	Phase 2	
NCT06014658	Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors	Drug: Antibody-Drug Conjugate	MBrace Therapeutics	Phase 1	
NCT05973487	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors	Biological: TSC-204-A0201 Biological: TSC-204-C0702 Biological: TSC-200-A0201 Biological: TSC-204-A0201 + TSC-204-C0702 Biological: TSC-204-A0201 + TSC-200-A0201	TScan Therapeutics, Inc.	Phase 1	
NCT05972135	Outpatient Administration of Teclistamab for Multiple Myeloma	Drug: Teclistamab Drug: Tocilizumab	SCRI Development Innovations, LLC Janssen Research & Development, LLC	Phase 2	
NCT05835206	Further MT for Antibiotic-Resistant Bacterial Colonization in Inpatients	Drug: Microbiome Therapeutic Drug: Placebo	Emory University Centers for Disease Control and Prevention	Phase 2	
NCT05987332	IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Drug: IDE196 Drug: Crizotinib Drug: Pembrolizumab Drug: Ipilimumab Drug: Nivolumab Drug: Dacarbazine	IDEAYA Biosciences	Phase 2 Phase 3	
NCT05984199	Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant	Biological: VCAR33	Vor Biopharma	Phase 1 Phase 2	
NCT06060457	A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age	Biological: Placebo Biological: mRNA-1345 Biological: Fluzone HD	ModernaTX, Inc.	Phase 3	
NCT06045806	A Study to Compare the Efficacy and Safety of Idecabtagene vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation	Biological: idecabtagene vicleucel Drug: Lenalidomide Drug: Fludarabine Drug: Cyclophosphamide	Bristol-Myers Squibb	Phase 3	
NCT06045221	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	Drug: Orforglipron Drug: Semaglutide	Eli Lilly and Company	Phase 3	
NCT06033196	Tocilizumab in Lung Transplantation	Drug: Tocilizumab Drug: Placebo for Tocilizumab	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 미국 81건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06007690	A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma	Drug: Belzupacap Sarotalocan Device: Suprachoroidal Microinjector Device: Infrared Laser Device: Sham Infrared Laser Device: Sham Microinjector Drug: Sham Treatment	Aura Biosciences	Phase 3	
NCT05949684	ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions	Biological: Luspatercept Biological: Epoetin Alfa	Bristol-Myers Squibb	Phase 3	
NCT05878717	A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease	Biological: Belimumab Other: Placebo	GlaxoSmithKline	Phase 3	
NCT05743270	Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Biological: RP3 Other: CCRT(concurrent chemoradiation therapy) Other: carboplatin and paclitaxel Biological: nivolumab	Replimune Inc. Bristol-Myers Squibb	Phase 2	
NCT05873205	Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation	Biological: Isatuximab	Memorial Sloan Kettering Cancer Center Sanofi	Phase 2	
NCT05748197	A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia	Biological: ADCLEC.syn1 CAR T cells Drug: Conditioning chemotherapy	Memorial Sloan Kettering Cancer Center Takeda	Phase 1	
NCT05695391	SCOPE HIM SCOPE HIM	Biological: Coagulation Factor VIIa (Recombinant)	Laboratoire français de Fractionnement et de Biotechnologies	Phase 3	
NCT05904886	A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)	Drug: Atezolizumab Drug: Bevacizumab Drug: Tiragolumab Other: Placebo	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	
NCT05199688	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)	Drug: Satralizumab	Hoffmann-La Roche	Phase 3	

○ 영국 11건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT04856215	90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia	Drug: 90-Yttrium-labelled anti-CD66 monoclonal antibody	Great Ormond Street Hospital for Children NHS Foundation Trust	Phase 2	
NCT06052306	A Study to Learn How Safe the Study Treatment Actinium-225-macropapulgifamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)	Drug: BAY3546828 Drug: BAY2616505 Drug: BAY2315493	Bayer	Phase 1	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 영국 11건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05965479	Developing ctDNA Guided Adjuvant Therapy for Gastroesophageal Cancer	Drug: Trastuzumab deruxtecan	University of Southampton AstraZeneca Natera, Inc.	Phase 2	
NCT05615818	Personalized Medicine for Advanced Biliary Cancer Patients	Drug: Futibatinib Drug: Ivosidenib Drug: Zanidatamab Drug: Trastuzumab Drug: Neratinib Drug: Encorafenib Drug: Binimetinib Drug: Niraparib Drug: Cisplatin Drug: Gemcitabine	UNICANCER Cancer Research UK & UCL Cancer Trials Centre Belgian Group of Digestive Oncology National Cancer Institute, France Cancer Research UK 등	Phase 3	
NCT06045806	A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucef With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation	Biological: idecabtagene vicleucef Drug: Lenalidomide Drug: Fludarabine Drug: Cyclophosphamide	Bristol-Myers Squibb	Phase 3	
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	
NCT05878717	A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease	Biological: Belimumab Other: Placebo	GlaxoSmithKline	Phase 3	
NCT05257083	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucef Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Daratumumab Drug: Bortezomib Drug: Lenalidomide Drug: Dexamethasone Drug: Cilta-cell Drug: Cyclophosphamide Drug: Fludarabine	European Myeloma Network Janssen Research & Development, LLC	Phase 3	
NCT05718297	Brigatinib Post Definitive Chemoradiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	
NCT05743270	Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Biological: RP3 Other: CCRT(concurrent chemoradiation therapy) Other: carboplatin and paclitaxel Biological: nivolumab	Replimune Inc. Bristol-Myers Squibb	Phase 2	
NCT05199688	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)	Drug: Satralizumab	Hoffmann-La Roche	Phase 3	

○ 프랑스 13건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05654753	The Efficacy of Fecal Microbiota Transplantation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment	Drug: active FMT Drug: Placebo	Assistance Publique - Hôpitaux de Paris Fondation Arthritis & Clarins Worldwide 2016	Phase 2 Phase 3	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 프랑스 13건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06038331	Use of a Treated, Devascularized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis	Biological: SclerFIX-IP	TBF Genie Tissulaire	Phase 2	
NCT06034262	Use of a Treated, Devascularized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis	Biological: SclerFIX-IP	TBF Genie Tissulaire	Phase 2	
NCT05622071	Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions	Drug: Tislelizumab	UNICANCER	Phase 2	
NCT05615818	Personalized Medicine for Advanced Biliary Cancer Patients	Drug: Futibatinib Drug: Ivosidenib Drug: Zanidatamab Drug: Trastuzumab Drug: Neratinib Drug: Encorafenib Drug: Binimetinib Drug: Niraparib Drug: Cisplatin Drug: Gemcitabine	UNICANCER Cancer Research UK & UCL Cancer Trials Centre Belgian Group of Digestive Oncology National Cancer Institute, France Cancer Research UK 등	Phase 3	
NCT06045806	A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucef With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation	Biological: idecabtagene vicleucef Drug: Lenalidomide Drug: Fludarabine Drug: Cyclophosphamide	Bristol-Myers Squibb	Phase 3	
NCT05949684	ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions	Biological: Luspatercept Biological: Epoetin Alfa	Bristol-Myers Squibb	Phase 3	
NCT05257083	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucef Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Daratumumab Drug: Bortezomib Drug: Lenalidomide Drug: Dexamethasone Drug: Cilta-cell Drug: Cyclophosphamide Drug: Fludarabine	European Myeloma Network Janssen Research & Development, LLC	Phase 3	
NCT05878717	A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease	Biological: Belimumab Other: Placebo	GlaxoSmithKline	Phase 3	
NCT05743270	Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Biological: RP3 Other: CCRT(concurrent chemoradiation therapy) Other: carboplatin and paclitaxel Biological: nivolumab	Replimune Inc. Bristol-Myers Squibb	Phase 2	
NCT05718297	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 프랑스 13건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05199688	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)	Drug: Satralizumab	Hoffmann-La Roche	Phase 3	

○ 독일 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05937295	FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition	Drug: Fusion-VAC-XS15	University Hospital Tuebingen	Phase 1	
NCT06045806	A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucl With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation	Biological: ideo cabtagene vicleucl Drug: Lenalidomide Drug: Fludarabine Drug: Cyclophosphamide	Bristol-Myers Squibb	Phase 3	
NCT05949684	ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions	Biological: Luspatercept Biological: Epoetin Alfa	Bristol-Myers Squibb	Phase 3	
NCT05257083	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucl Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Daratumumab Drug: Bortezomib Drug: Lenalidomide Drug: Dexamethasone Drug: Ciltacabtagene Drug: Cyclophosphamide Drug: Fludarabine	European Myeloma Network Janssen Research & Development, LLC	Phase 3	
NCT05878717	A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease	Biological: Belimumab Other: Placebo	GlaxoSmithKline	Phase 3	
NCT05743270	Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Biological: RP3 Other: CCRT(concurrent chemoradiation therapy) Other: carboplatin and paclitaxel Biological: nivolumab	Replimune Inc. Bristol-Myers Squibb	Phase 2	
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	

○ 중국 23건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06041035	A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors	Drug: QLS31905 Drug: Nab paclitaxel Drug: Gemcitabine Drug: Oxaliplatin Drug: Capecitabine Drug: Cisplatin	Qilu Pharmaceutical Co., Ltd.	Phase 1 Phase 2	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 중국 23건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05985863	Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure	Drug: standard medical treatment Drug: Placebo Drug: hUC- MSC Drug: hUC- MSC_Prolonged	Beijing 302 Hospital Shulan (Hang Zhou) Hospital Beijing Youan Hospital Shenzhen Third People's Hospital Shen Zhen Wingor Biotechnology CO. LTD	Phase 1 Phase 2	
NCT06062641	Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL	Drug: SR-GDP	Ruijin Hospital	Phase 2	
NCT06056752	QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia	Biological: QH103 Cell Injection Drug: Fludarabine Drug: Cyclophosphamide	Anhui Provincial Hospital	Phase 1	
NCT06055816	Gemcitabine Combined With Endostar and Envafoimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma	Drug: Endostar and Envafoimab	Zhejiang Cancer Hospital	Phase 2	
NCT06054906	Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer	Drug: sintilimab+metronomic PLOF	Huashan Hospital	Phase 2	
NCT06047080	An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma	Drug: Glofitamab Drug: Polatuzumab vedotin Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Prednisone	Hoffmann-La Roche	Phase 3	
NCT06038058	A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies	Drug: BRY812 for injection	BioRay Pharmaceutical Co., Ltd.	Phase 1	
NCT06028633	Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients	Drug: pembrolizumab Drug: lenvatinib Drug: albumin-bound paclitaxel	Peking University First Hospital Merck Sharp & Dohme LLC	Phase 2	
NCT06010875	A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors	Biological: CD70 CAR-T cells	Chongqing Precision Biotech Co., Ltd The First Affiliated Hospital of Nanchang University	Phase 1	
NCT06010862	Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors	Biological: CEA CAR-T cells	Chongqing Precision Biotech Co., Ltd The First Affiliated Hospital of Nanchang University	Phase 1	
NCT05979155	A Study of NWY001 in Subjects With Advanced Solid Tumors	Biological: NWY001	Chipscreen Biosciences, Ltd.	Phase 1	
NCT05975151	Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer	Drug: Pseudomonas aeruginosa	Qilu Hospital of Shandong University	Phase 2	
NCT05952947	HRYZ-T101 Injection for HPV18 Positive Solid Tumor	Biological: HRYZ-T101 Injection Drug: Fludarabine + Cyclophosphamide	SYZ Cell Therapy Co..	Phase 1	
NCT05881668	MSC-EV in Acute-on-Chronic Liver Failure After Liver Transplantation	Biological: MSC-EV	Third Affiliated Hospital, Sun Yat-Sen University	Phase 1	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 중국 23건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05894889	Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC	Biological: Pembrolizumab 200 mg IV infusion	Peking University Merck Sharp & Dohme LLC Shanghai Pulmonary Hospital, Shanghai, China Guangdong Provincial People's Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2	
NCT05624099	Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.	Drug: camrelizumab Drug: Paclitaxel drugs Drug: Platinum drug Radiation: Radiation	Fujian Cancer Hospital	Phase 2	
NCT05996224	Allogenic Adipose-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis	Biological: Mesenchymal progenitor cells Drug: Sodium Hyaluronate Injection	Cellular Biomedicine Group Ltd.	Phase 3	
NCT06036927	A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps	Drug: TQC2731 injection Drug: TQC2731 matching placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2	
NCT05998759	Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia	Biological: Telitacicept Drug: Placebo	Beijing Hospital The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial) Peking University People's Hospital Peking University Third Hospital First Affiliated Hospital, Sun Yat-Sen University Guangdong Provincial People's Hospital	Phase 2	
NCT06045221	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	Drug: Orforglipron Drug: Semaglutide	Eli Lilly and Company	Phase 3	
NCT05949684	ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions	Biological: Luspatercept Biological: Epoetin Alfa	Bristol-Myers Squibb	Phase 3	
NCT05878717	A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease	Biological: Belimumab Other: Placebo	GlaxoSmithKline	Phase 3	

○ 일본 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05879653	Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)	Drug: MK-3475 Drug: ASG-22CE Procedure: maximal TURBT Radiation: Radiation therapy	Kyoto University Hospital University of Tsukuba Osaka Metropolitan University Kobe City Medical Center General Hospital Merck Sharp & Dohme LLC Astellas Pharma Inc	Phase 2	
NCT06002490	A Study to Evaluate P1101 in Japanese PV Patients	Drug: P1101 Drug: Low-dose aspirin Procedure: Phlebotomy	PharmaEssentia Japan K.K.	Phase 3	
NCT06045221	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	Drug: Orforglipron Drug: Semaglutide	Eli Lilly and Company	Phase 3	

해외 바이오의약품 임상 현황 ('23년 9월 4주)

한국바이오의약품협회, 2023.10.04.

○ 일본 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06045806	A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation	Biological: iclecabtagene vicleucel Drug: Lenalidomide Drug: Fludarabine Drug: Cyclophosphamide	Bristol-Myers Squibb	Phase 3	
NCT05257083	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma	Drug: Daratumumab Drug: Bortezomib Drug: Lenalidomide Drug: Dexamethasone Drug: Cilta-cel Drug: Cyclophosphamide Drug: Fludarabine	European Myeloma Network Janssen Research & Development, LLC	Phase 3	
NCT05878717	A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease	Biological: Belimumab Other: Placebo	GlaxoSmithKline	Phase 3	
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	